Trial Profile
Sitagliptin Acute Coronary Syndrome Randomised Investigation Registry
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Antihyperglycaemics
- Indications Acute coronary syndromes; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SAMURAI-REGISTRY
- 04 Jul 2019 Status changed from not yet recruiting to discontinued.
- 05 Mar 2012 New trial record